A Sharply Defined Pattern of Central Retinal Thinning
A well-kept lawn sometimes develops one small, perfectly round patch of bare earth right in the middle, while the grass surrounding it stays thick, green, and completely unaffected. Central areolar choroidal dystrophy produces a strikingly similar picture under retinal examination — a well-defined patch of atrophy positioned right beneath the macula, while the retina and choroid around it stay essentially undisturbed. That unusually sharp border is typically the very first thing a specialist notices.
Patients in Uganda generally come to us with this condition already in their thirties or forties, commonly after an unrelated eye appointment uncovered a pale, curiously well-defined patch — something an alert local eye doctor recognised right away as inconsistent with the kind of ageing-related change expected at that point in life.
Most people only realise anything has changed by comparing how things used to be — a menu that used to be effortless to read now takes real concentration, or they find themselves tilting their head to shift a face slightly away from dead centre. Over time, a sharply bordered dark or grey area settles right in the middle of a person's vision, though ordinary activities — walking through a full room, locating a door — remain completely unaffected, since the disease only touches that narrow central zone and leaves vision in low light entirely alone.
Most confirmed cases can be traced to a defect in the PRPH2 gene, which under normal conditions builds a structural protein that photoreceptor cells rely on to hold their shape and do their job properly. Once that protein malfunctions, three closely stacked layers under the macula — the choriocapillaris, the retinal pigment epithelium, and the photoreceptors sitting on top — break down as a unit, though the damage stays tightly boxed into that single small region without drifting further. This tends to run in families as a dominant trait, appearing generation after generation.
What draws attention on examination is just how unusually crisp the border of the atrophic area looks, as though someone had traced it with a straightedge, and fundus autofluorescence is the best tool available for mapping that boundary precisely. OCT reveals how much photoreceptor tissue survives right at the very edge — often the most useful piece of information going forward — and a largely normal ERG reading is reassuring, since it tells us the damage has genuinely stayed contained rather than spreading. A PRPH2 genetic test wraps up the diagnostic process.
Instead of a rigid, fixed schedule, we let the pace at which the atrophic zone is actually growing dictate the plan, judged through repeated imaging spaced out over time rather than a single snapshot. Qualifying patients are considered for regenerative stem cell therapy, with the aim of protecting retina that's still working near the edge of the affected zone, and as that central blind spot takes clearer shape, we help build practical low-vision approaches around each person's specific pattern of loss.
Not at all — that's actually exactly what we'd expect rather than a reason for concern. This condition only touches a small central area and spares the rod cells responsible for night vision entirely, so seeing in low light usually stays just as reliable even while reading and recognising faces gets harder.
There's no guaranteed stopping point — some patients see barely any change across ten years, while others notice clearer progress within a much shorter span. That variability is exactly why we track things through repeat imaging rather than assuming any fixed rate.
The resemblance can be striking, but the two arise from completely different causes and at different points in life — yours from an inherited gene fault decades ahead of schedule, hers from ordinary age-related changes arriving much later. Genetic testing combined with the age of onset is what actually tells them apart.
For most patients, that's unlikely — everyday mobility and a sense of direction generally hold up fine, since the disease sticks to one defined central area rather than spreading into the wider visual field that guides how we navigate day to day.